Program
Sirolimus
Also written as “sirolimus”, “Rapamycin” and “Sirolimus for Injection (Albumin-bound)”.
Its studies are mostly in Renal Insufficiency · Kidney Failure, Chronic · Breast Neoplasms · Tuberous Sclerosis · Uveitis, led by 18 companies.
Drug pageSirolimus: every studyMany companies study it; this page follows only the 65 they lead. All 505 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizerits history only | 260 open or running | phase 4since Sep 4, 2002 | May 17, 2002 | none ahead |
| CSPC Pharmaceutical Groupits history only | 85 open or running | phase 3since Apr 8, 2025 | Oct 25, 2021 | Oct 2027phase 1 · NCT06941142 |
| Santen Pharmaceuticalits history only | 70 open or running | phase 3since May 19, 2011 | Nov 15, 2006 | none ahead |
| Astellas Pharmaits history only | 31 open or running | phase 4since May 31, 2011 | May 31, 2011 | Oct 31, 2027phase 2 · NCT07052929 |
| Umoja Biopharmaits history only | 33 open or running | phase 2since Jul 24, 2026 | Jul 25, 2024 | Mar 2029phase 1 · NCT06528301 |
| AgelessRxits history only | 21 open or running | phase 3since Dec 18, 2024 | Jul 13, 2020 | none ahead |
| Dr. Reddy's Laboratoriesits history only | 20 open or running | phase 1since Nov 18, 2014 | Nov 18, 2014 | none ahead |
| Hoffmann-La Rocheits history only | 20 open or running | phase 4since Jul 15, 2005 | Jul 15, 2005 | none ahead |
| Nobelpharmaits history only | 20 open or running | phase 1since Dec 3, 2018 | Dec 3, 2018 | none ahead |
| Vascular Therapiesits history only | 20 open or running | phase 3since Jul 29, 2015 | Jul 29, 2015 | none ahead |
| AFT Pharmaceuticalsits history only | 11 open or running | phase 2since Feb 22, 2026 | Feb 22, 2026 | Oct 2027phase 2 · NCT07436611 |
| Aucta Pharmaceuticalsits history only | 10 open or running | phase 2since Dec 1, 2017 | Dec 1, 2017 | none ahead |
| Chong Kun Dang Pharmaceuticalits history only | 11 open or running | phase 4since Jan 3, 2022 | Jan 3, 2022 | none ahead |
| Concept Medicalits history only | 11 open or running | phase 3since Jan 21, 2026 | Jan 21, 2026 | Dec 2027phase 3 · NCT07359807 |
| Dermatology Specialties Limited Partnershipits history only | 10 open or running | phase 3since Jan 29, 2019 | Jan 29, 2019 | none ahead |
| Eli Lillyits history only | 11 open or running | phase 2since May 11, 2020 | May 11, 2020 | Feb 2027phase 2 · NCT04411654 |
| Nanjing IASO Biotechnologyits history only | 11 open or running | phase 1since Dec 10, 2024 | Dec 10, 2024 | May 21, 2028phase 1 · NCT06743503 |
| TransDermits history only | 10 open or running | phase 1since Feb 5, 2014 | Feb 5, 2014 | none ahead |
- Named in CSPC Pharmaceutical Group’s own pipeline as
sirolimus for injection (albumin-bound)
, phase 4, as of Aug 20, 2026 (source).
Also a collaborator on its studies: Basilea Pharmaceutica International and MacuSight.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 46 studies since Aug 1, 2005.
- Nov 14, 2022Phase 2 study in Perivascular Epithelioid Cell NeoplasmsCSPC Pharmaceutical Group · NCT05625919 · 54 enrolled · China
- Jul 25, 2024Umoja Biopharma’s first study: phase 1 study in Lymphoma, B-CellNew to Umoja BiopharmaUmoja Biopharma · NCT06528301 · 106 planned · United States, Australia
- Dec 10, 2024Nanjing IASO Biotechnology’s first study: phase 1 study in RecurrenceNew to Nanjing IASO BiotechnologyNanjing IASO Biotechnology · NCT06743503 · 70 planned · China
- Dec 18, 2024Phase 3 study in LongevityAgelessRx · NCT07092618 · 150 planned · United States
- Apr 8, 2025Phase 3 study in Breast NeoplasmsCSPC Pharmaceutical Group · NCT06929325 · 312 planned · China
- Apr 16, 2025Phase 1 study in Advanced Breast CancerCSPC Pharmaceutical Group · NCT06941142 · 382 planned
- Apr 26, 2025Phase 2 study in Breast NeoplasmsCSPC Pharmaceutical Group · NCT06957379 · 78 enrolled · China
- Jun 30, 2025Phase 2 study in Myopathies, Structural, CongenitalAstellas Pharma · NCT07052929 · 9 planned · United States, Canada
- Sep 3, 2025Phase 3 study in Gastroenteropancreatic Neuroendocrine TumorsCSPC Pharmaceutical Group · NCT07165886 · 298 planned · China
- Jan 21, 2026Concept Medical’s first study: phase 3 study in Peripheral Arterial DiseaseNew to Concept MedicalConcept Medical · NCT07359807 · 478 planned
- Feb 22, 2026AFT Pharmaceuticals’ first study: phase 2 study in Hemangioma, CapillaryNew to AFT PharmaceuticalsAFT Pharmaceuticals · NCT07436611 · 30 planned · United States, Spain
- Jun 29, 2026Phase 2 study in Hemangioendothelioma, EpithelioidCSPC Pharmaceutical Group · NCT07684287 · 40 planned · China
- Jul 24, 2026Phase 1 study in Multiple MyelomaUmoja Biopharma · NCT07735546 · 100 planned · Australia
- Jul 24, 2026Phase 2 study in Lymphoma, B-CellPhase 2 reachedUmoja Biopharma · NCT07735533 · 274 planned · United States
Ahead
- Feb 2027Primary completion: phase 2 study in Gaucher DiseaseEli Lilly · NCT04411654
- Oct 2027Primary completion: phase 2 study in Hemangioma, CapillaryAFT Pharmaceuticals · NCT07436611
- Oct 2027Primary completion: phase 1 study in Advanced Breast CancerCSPC Pharmaceutical Group · NCT06941142
- Oct 31, 2027Primary completion: phase 2 study in Myopathies, Structural, CongenitalAstellas Pharma · NCT07052929
TargetBeta
“A natural macrocyclic lactone produced by the bacterium Streptomyces hygroscopicus, with immunosuppressant properties. In cells, sirolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian …”NCIt, read by Claude
“FK506-binding protein 1A inhibitor”ChEMBL 37, by rule
Other programs on MTOR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| gedatolisibrule | Pfizer | phase 3 | 9 |
| PI3K/mTOR Kinase Inhibitor WXFL10030390rule | shanghai-jiatan-pharmatech-co-ltd | phase 3 | 6 |
| sapanisertibrule | Takeda | phase 2 | 14 |
Studies
The newest 60 of 65 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07735546Multiple Myeloma · Australia | 1 | Recruiting | Umoja Biopharma | Dec 31, 2029 | 100 |
| NCT07735533Lymphoma, B-Cell · United States | 2 | Recruiting | Umoja Biopharma | Aug 2031 | 274 |
| NCT07684287Hemangioendothelioma, Epithelioid · China | 2 | Not yet recruiting | CSPC Pharmaceutical Group | Nov 30, 2027 | 40 |
| NCT07436611Hemangioma, Capillary · United States, Spain | 2 | Not yet recruiting | AFT Pharmaceuticals | Oct 2027 | 30 |
| NCT07359807Peripheral Arterial Disease | 3 | Not yet recruiting | Concept Medical | Dec 2027 | 478 |
| NCT07165886Gastroenteropancreatic Neuroendocrine Tumors · China | 3 | Recruiting | CSPC Pharmaceutical Group | Aug 29, 2028 | 298 |
| NCT07052929Myopathies, Structural, Congenital · United States, Canada | 2 | Recruiting | Astellas Pharma | Oct 31, 2027 | 9 |
| NCT06957379Breast Neoplasms · China | 2 | Active, not recruiting | CSPC Pharmaceutical Group | Jun 2025 | 78 |
| NCT06941142Advanced Breast Cancer | 1 | Not yet recruiting | CSPC Pharmaceutical Group | Oct 2027 | 382 |
| NCT06929325Breast Neoplasms · China | 3 | Not yet recruiting | CSPC Pharmaceutical Group | Oct 2026 | 312 |
| NCT07092618Longevity · United States | 3 | Recruiting | AgelessRx | Aug 2025 | 150 |
| NCT06743503Recurrence · China | 1 | Recruiting | Nanjing IASO Biotechnology | May 21, 2028 | 70 |
| NCT06528301Lymphoma, B-Cell · United States, Australia | 1 | Recruiting | Umoja Biopharma | Mar 2029 | 106 |
| NCT05625919Perivascular Epithelioid Cell Neoplasms · China | 2 | UNKNOWN | CSPC Pharmaceutical Group | Nov 2024 | 54 |
| NCT05508620Malignant Solid Tumors | 1 | UNKNOWN | CSPC Pharmaceutical Group | Dec 2024 | 270 |
| NCT05425056Kidney Failure, Chronic · United States, United Kingdom | 3 | Completed | Vascular Therapies | Mar 18, 2025 | 136 |
| NCT05193565Kidney Transplantation · South Korea | 4 | Active, not recruiting | Chong Kun Dang Pharmaceutical | Jul 2026 | 206 |
| NCT05125523Advanced Solid Tumors · China | 1 | UNKNOWN | CSPC Pharmaceutical Group | Jun 2024 | 264 |
| NCT04488601Aging · United States | 2 | Completed | AgelessRx | Dec 30, 2023 | 129 |
| NCT04411654Gaucher Disease · United States, United Kingdom | 2 | Active, not recruiting | Eli Lilly | Feb 2027 | 7 |
| NCT03972462Bioavailability Study · United States | 1 | Completed | Nobelpharma | Jun 17, 2019 | 12 |
| NCT03826628Tuberous Sclerosis · United States, Australia, Czechia and more | 3 | Completed | Dermatology Specialties Limited Partnership | Sep 1, 2022 | 107 |
| NCT03765944Bioequivalence Study · Japan | 1 | Completed | Nobelpharma | Dec 29, 2018 | 10 |
| NCT03363763Tuberous Sclerosis · United States, China | 2 | Terminated | Aucta Pharmaceuticals | Mar 24, 2023 | 24 |
| NCT02686619Renal Transplantation · France | 3 | Completed | Hoffmann-La Roche | Jan 2011 | 237 |
| NCT02513303Kidney Failure, Chronic · United States | 3 | Completed | Vascular Therapies | Jun 2021 | 269 |
| NCT02296762Healthy · India | 1 | Completed | Dr. Reddy's Laboratories | Feb 2010 | 36 |
| NCT02296749Healthy · India | 1 | Completed | Dr. Reddy's Laboratories | Jan 2010 | 60 |
| NCT02251938Non-Infectious Uveitis of the Posterior Segment of the Eye · United States, Austria, France and more | 3 | Completed | Santen Pharmaceutical | Nov 1, 2017 | 60 |
| NCT02152007Pachyonychia Congenita · United States | 1 | Completed | TransDerm | Jul 2015 | 15 |
| NCT01809860Healthy Subjects · United States | 1 | Completed | Astellas Pharma | Jan 2012 | 22 |
| NCT01363752Acute Kidney Injury · Australia, Austria, Belarus and more | 4 | Completed | Astellas Pharma | Sep 18, 2013 | 853 |
| NCT01358266Uveitis · United States, Argentina, Austria and more | 3 | Completed | Santen Pharmaceutical | Sep 2016 | 592 |
| NCT01236378Transplant Rejection · China | 1 | Completed | Pfizer | Apr 2011 | 24 |
| NCT00895583Graft Rejection · United States, Argentina, Australia and more | 4 | Completed | Pfizer | Aug 2013 | 254 |
| NCT00814944Dry Eye Syndromes · United States | 2 | Completed | Santen Pharmaceutical | Oct 2009 | 143 |
| NCT00766337Macular Degeneration · United States | 2 | Terminated | Santen Pharmaceutical | Nov 2009 | 62 |
| NCT00712491Macular Degeneration · United States | 2 | Terminated | Santen Pharmaceutical | Nov 2009 | 20 |
| NCT00656643Diabetic Macular Edema · United States | 2 | Completed | Santen Pharmaceutical | Nov 2009 | 131 |
| NCT00519116Kidney Transplantation | 4 | Completed | Pfizer | 150 | |
| NCT00518375Kidney Transplantation | 4 | Completed | Pfizer | 250 | |
| NCT00518271Kidney Transplantation | 2 | Completed | Pfizer | 120 | |
| NCT00507793Kidney Transplantation | 4 | Completed | Pfizer | 385 | |
| NCT00478608Renal Transplant · Korea, Republic of | 3 | Completed | Pfizer | Nov 2008 | 79 |
| NCT00470665Renal Allograft Recipients | 3 | Completed | Pfizer | 460 | |
| NCT00452361Kidney Transplantation · Taiwan | 4 | Terminated | Pfizer | Aug 2008 | 31 |
| NCT00428064Renal Transplantation | 3 | Completed | Pfizer | 408 | |
| NCT00401115Diabetic Retinopathy · United States | 1 | Completed | Santen Pharmaceutical | Jun 2008 | 50 |
| NCT00369382Renal Insufficiency · United States, Australia, Austria and more | 4 | Completed | Pfizer | Apr 2010 | 121 |
| NCT00311311Atherosclerosis · United States, Canada | 3 | Terminated | Pfizer | Dec 2010 | 72 |
| NCT00282217Renal Insufficiency · Spain | 4 | Completed | Pfizer | 100 | |
| NCT00266123Renal Insufficiency | 4 | Completed | Pfizer | 420 | |
| NCT00261820Renal Insufficiency | 4 | Completed | Pfizer | 160 | |
| NCT00254709Renal Insufficiency | 4 | Completed | Pfizer | 66 | |
| NCT00248313Kidney Diseases | 3 | Completed | Pfizer | 470 | |
| NCT00195481Renal Insufficiency · India | 4 | Completed | Pfizer | Dec 2005 | 100 |
| NCT00195273Graft vs Host Disease · Norway, Sweden | 3 | Completed | Pfizer | Jul 2008 | 61 |
| NCT00167947Renal Insufficiency · Italy | 3 | Completed | Pfizer | Jul 2007 | 150 |
| NCT00137345Kidney Transplant · United States, Argentina, Australia and more | 3 | Terminated | Pfizer | Aug 2006 | 500 |
| NCT00129961Skin Neoplasms · United States, Australia, Canada and more | 4 | Completed | Pfizer | Jan 2009 | 86 |
How it is read
Names in the registry
- “Sirolimus”, 28 entries
- “sirolimus”, 8 entries
- “Rapamycin”, 3 entries
- “Sirolimus for Injection (Albumin-bound)”, 3 entries
- “Rapamune® (Sirolimus)”, 3 entries
Conditions, from the studies’ own filings
- Renal Insufficiency, 7 studies
- Kidney Failure, Chronic, 3 studies
- Breast Neoplasms, 3 studies
- Tuberous Sclerosis, 2 studies
- Uveitis, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.